Diosynth Biotechnology (Research Triangle Park) Announces Agreement with VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.) for Process Development and Clinical Production of VGX-100 for the Treatment of Cancer

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Diosynth Biotechnology announced today that it has signed an agreement with VGX Pharmaceuticals for process development activities and cGMP production of clinical trial material for their biological therapeutic drug candidate VGX-100.